February 26, 2023
Financière de Tubize – Annual Report 2022
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: [email protected] Annual Report 2022 Regulated information25 February 2023…
Pharmaceuticals, Biotechnology and Life Sciences
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: [email protected] Annual Report 2022 Regulated information25 February 2023…
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER,…
CLINUVEL Financial Performance CLINUVEL Group financial performance for the half year ended 30 December, since first commercial sales. MELBOURNE, Australia,…
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under…
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –…
— Company expects to announce data for Factor VIII expression in non-human primates in 2023 — Strong cash balance of…
FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical…
CHATHAM, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage…
Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications Cash Runway…
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR…